&w=3840&q=100)
Lupin share price increases on rolling out eye medication; details here
Around 10:20 AM, Lupin share price continued to trade higher, up 1.07 per cent at ₹1,950.40 per share. In comparison, BSE Sensex was trading 0.22 per cent lower at 82,456.51 levels.
Why did Lupin share price rise today?
Lupin's share price rose today after the company announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, in the US market.
In a press release, the company said, 'Global pharma major Lupin Limited (Lupin) today announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, in the United States. Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent is bioequivalent to Lotemax Ophthalmic Suspension, 0.5 per cent, of Bausch & Lomb Inc.'
The drug is a generic version of Bausch & Lomb's Lotemax, and is used to treat steroid-responsive inflammatory conditions of the eye, including conjunctivitis, keratitis, iritis, and post-operative inflammation.
According to IQVIA MAT data for May 2025, the reference listed drug (RLD) Lotemax had estimated annual sales of around USD 55 million in the US. Track Stock Market LIVE Updates
Lupin Q4 results
The pharma major Lupin reported a 112.4 per cent year-on-year (Y-o-Y) jump in consolidated net profit at ₹782.4 crore for Q4FY25, compared to ₹368.2 crore in the year-ago period.
Revenue from operations rose 14.2 per cent Y-o-Y to ₹5,671 crore, up from ₹4,961 crore in Q4FY24. However, on a sequential basis, profit declined 8.9 per cent and revenue slipped 1.7 per cent.
Operationally, Ebitda grew 34.3 per cent Y-o-Y to ₹1,371 crore, while the Ebitda margin improved to 24.8 per cent from 21 per cent in the same quarter last year.
About Lupin
Lupin is among the leading Indian multinational pharmaceutical companies headquartered in Mumbai, known for its expertise in developing and commercialising generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs).
With operations spanning over 100 countries, including key markets like the US, India, South Africa, and regions across Asia Pacific, Latin America, Europe, and the Middle East, Lupin has established itself as a global player.
The company holds strong positions in therapeutic areas such as cardiovascular, diabetology, asthma, paediatrics, and central nervous system (CNS) disorders. Notably, it is also a global leader in anti-tuberculosis and cephalosporin segments.
Founded in 1968 by Desh Bandhu Gupta with a mission to combat life-threatening infectious diseases, Lupin has grown into a pharmaceutical powerhouse with a robust global footprint.
It operates multiple manufacturing facilities in India, including sites at Mandideep, Ankleshwar, Tarapur, and Vadodara, supported by a network of research centers and a large workforce. In addition to its pharmaceutical business, the company has expanded into diagnostics through its wholly owned subsidiary, Lupin Diagnostics, which operates a national reference laboratory in Navi Mumbai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
35 minutes ago
- Time of India
Graduates' ideas and plans must contribute meaningfully to nation: Ex-Isro chairman
Mandya: In today's competitive world, the number of graduates is steadily increasing, and their ideas and plans must contribute meaningfully to the nation, said S Somanath, former Isro chairman and current chancellor of Chanakya University. He delivered the convocation address at the 5th convocation of Adichunchanagiri University in BG Nagara in Nagamangala Taluk. "Until now, your life was in a different direction. From today, a new phase—your professional and personal life—begins. Alongside knowledge, your skills will now play a vital role. Always uphold values like character, integrity, and wholeness in your career and life," he advised the graduates. "India has made immense contributions to the world through its rich culture, and today it stands tall in the science and technology community through missions like 'Mangalyaan' and ' Chandrayaan-3 '," he said. He noted that modern technology, especially Artificial Intelligence, is now solving many complex problems. "There are several transformative changes taking place in space research and the health and pharmaceutical sectors. We are witnessing developments that are a matter of pride for our nation. Blockchain technology is now being used for financial regulation. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like How to Trade ETH/USD Without Holding Ether IC Markets Learn More Undo If success is accompanied by humility, it adds meaning to life," he said. A total of 1,882 candidates were conferred with various degrees at the convocation. Agriculture minister N Cheluvarayaswamy, who also spoke on the occasion, said, "Graduates are national assets. While many convocation ceremonies happen across the country, the value and significance of Adichunchanagiri University's convocation are unmatched. Adichunchanagiri mutt seer Nirmalanandanatha Swami is fulfilling the vision of former seer Balagangadharanatha Swami. The institution has achieved remarkable progress, and graduates must now focus on giving back to the nation. The challenges ahead are many—along with education, knowledge is essential. This esteemed institution is our pride," he added. Nirmalanandanatha Swami blessed and congratulated the gold medal winners, rank holders, and PhD awardees. During the convocation, 20 candidates were conferred with the PhD. Gold medallists Medicine - Dr Deekshita K Iyer Engineering - B Varsha, Likhith R Arbia, Muskaan Bindu VR, Preethi KD, Rekharani, Nityashree S Jain, Manoj Gowda DK, Puneeth Kumar, Ullas S, Jeevitha R, Jnana DN.
Economic Times
43 minutes ago
- Economic Times
US stock market today dances near record heights: S&P 500 flirts with all-time high, Nasdaq soars on tech euphoria, Dow holds steady as Fed decision looms
US stock market today trends analysis shows Wall Street holding steady as investors digest a wave of strong corporate earnings, a highly anticipated Federal Reserve meeting, and improving global economic signals. With the S&P 500 hovering near record highs and the Nasdaq pushing upward on tech momentum, market sentiment remains cautiously optimistic. As tariff talks with China continue and inflation shows signs of cooling, traders are closely watching for any policy shifts or surprises that could influence the rally. Synopsis US stock market today trends analysis shows Wall Street moving with cautious optimism as the S&P 500 flirts with record highs and tech stocks push the Nasdaq up. Strong Q2 earnings from companies like SoFi and Sarepta are fueling the rally, while investors await signals from the ongoing Federal Reserve meeting. Dow Jones is flat amid mixed industrial results. With global trade talks in motion and inflation showing signs of cooling, market sentiment is upbeat but watchful. U.S. stock market is riding high today, July 29, 2025, as investor confidence strengthens on the back of strong earnings reports, surging tech stocks, and hopes of policy clarity from the Federal Reserve. Wall Street's key indexes—the S&P 500, Nasdaq, and Dow Jones—are trading in positive territory as the market looks to build on recent gains that pushed the S&P 500 to a fresh all-time high just yesterday. ADVERTISEMENT With inflation cooling, global trade uncertainties easing slightly, and corporate profits showing resilience, today's trading action reflects a cautiously optimistic mood among investors. Let's break down what's driving the U.S. stock market today and what it means for investors and traders alike. S&P 500 is near record levels, driven by large-cap strength. is near record levels, driven by large-cap strength. Nasdaq is outperforming due to strong tech earnings. is outperforming due to strong tech earnings. Dow Jones is steady, reflecting mixed sector performance. is steady, reflecting mixed sector performance. Strong Q2 earnings are fueling investor confidence. earnings are fueling investor confidence. Fed's meeting is the next big catalyst for the market The S&P 500, represented by the SPDR S&P 500 ETF Trust (SPY), is currently trading at 638.47 USD, reflecting a modest intraday gain of +0.24%. This move brings it just shy of its all-time closing high of 638.88 USD, set on July 28, 2025. ALSO READ: Fed meeting and rate cut buzz take center stage as Powell weighs tariffs and inflation—will markets get the dovish signal they're hoping for? Investors appear to be piling into large-cap names, especially in sectors like technology, industrials, and financials, which are benefiting from robust earnings reports and confidence that the U.S. economy can avoid a recession this year. ADVERTISEMENT As the Federal Reserve's two-day meeting kicks off, the market is expecting no major surprises. Investors are watching closely for any signals on the interest rate trajectory for the rest of the year. Current Level: 638.47 638.47 Change: +1.53 points ( +0.24% ) +1.53 points ( ) Today's High: 638.88 638.88 Today's Low: 637.97 637.97 Status: Just shy of its record closing high set yesterday. The Nasdaq, tracked through the Invesco QQQ Trust (QQQ), is seeing solid gains of +0.69%, currently priced at 572.06 USD. Investors continue to favor tech and AI-related stocks, which have been leading the broader market's year-to-date performance. ADVERTISEMENT Today's rally is largely being fueled by strong Q2 earnings and upward guidance from several prominent tech companies, reinforcing the belief that innovation-driven growth remains intact. Key contributors to the Nasdaq's performance include firms in the cloud computing, software, and semiconductors sectors. The Dow Jones Industrial Average, represented by the SPDR Dow Jones ETF (DIA), is relatively unchanged, ticking slightly up by 0.04% to 448.53 USD. This flat performance mirrors a mixed bag of earnings results from key industrial and consumer-facing companies. ADVERTISEMENT While some Dow components such as Boeing and Procter & Gamble are contributing to mild gains, weakness in UnitedHealth, UPS, and Whirlpool is capping broader upside. Investors are showing signs of caution as traditional blue-chip stocks respond unevenly to macroeconomic data and earnings results. One of the key drivers of today's rally is the robust earnings season underway. Companies across several sectors have reported Q2 results that either beat or met Wall Street expectations, helping to calm fears of a looming earnings recession. ADVERTISEMENT SoFi Technologies (SOFI) surged over 11% after reporting a 44% year-over-year revenue jump and lifting its full-year guidance. surged over after reporting a and lifting its full-year guidance. Sarepta Therapeutics (SRPT) jumped over 36% as the FDA greenlit its Duchenne muscular dystrophy gene therapy product, Elevidys , for renewed shipments. jumped over as the FDA greenlit its Duchenne muscular dystrophy gene therapy product, , for renewed shipments. Cadence Design Systems gained more than 8% after delivering a strong earnings beat and raising its guidance for the rest of the year. These upbeat earnings have acted as a buffer against market volatility and created a risk-on sentiment, particularly in growth and innovation-led sectors. Not all sectors are participating in the rally. The healthcare and consumer discretionary sectors are facing pressure today, dragging down sentiment in parts of the market. UnitedHealth Group dropped nearly 6% after missing Q2 earnings estimates and trimming its 2025 profit outlook due to rising medical costs. dropped nearly after missing Q2 earnings estimates and trimming its 2025 profit outlook due to rising medical costs. Novo Nordisk , a major pharmaceutical player, plunged over 21% after lowering its annual forecast for blockbuster drugs Ozempic and Wegovy due to supply chain disruptions. , a major pharmaceutical player, plunged over after lowering its annual forecast for blockbuster drugs Ozempic and Wegovy due to supply chain disruptions. Whirlpool fell about 17% following a disappointing quarterly report and guidance cut, citing heightened competition from low-cost imports. These declines highlight the uneven nature of the post-pandemic recovery, as certain sectors remain more exposed to cost pressures and global disruptions. Markets are treading carefully as the Federal Reserve kicks off its two-day policy meeting. While most analysts expect the Fed to hold interest rates steady, investors are on high alert for any changes in tone that could affect rate expectations for the rest of 2025. Recent data has shown a gradual cooling of inflation, providing room for the Fed to remain cautious. However, any hints at rate hikes or a more hawkish stance could unsettle the current market rally. Fed Chair Jerome Powell's remarks tomorrow will be closely scrutinized for signs of shifting sentiment. Stock % Change Key Driver SoFi Technologies (SOFI) +11% Revenue beat, raised guidance Sarepta Therapeutics (SRPT) +36% FDA approval of Elevidys Cadence Design Systems +8.2% Strong earnings, higher outlook Novo Nordisk -21% Lowered drug forecast Whirlpool -17% Weak earnings, rising import competition UnitedHealth Group -6% Missed earnings, rising costs On the global front, the International Monetary Fund (IMF) has revised its 2025 global GDP growth forecast upward to 3.0%, citing stronger-than-expected consumer demand and improved resilience in emerging markets. However, the IMF also warned of potential downside risks, especially if trade disputes between the U.S. and China escalate further. Ongoing talks in Sweden between U.S. and Chinese officials have offered a glimmer of hope, and markets are reacting positively to any signs of progress. Meanwhile, investors continue to monitor President Donald Trump's unpredictable tariff policies, which have introduced new uncertainty into global trade dynamics. A closer look at sector performance reveals where market strength is concentrated: Technology : Driven by AI, chipmakers, and cloud software leaders posting solid earnings. : Driven by AI, chipmakers, and cloud software leaders posting solid earnings. Industrials : Boosted by Boeing's performance and infrastructure spending optimism. : Boosted by Boeing's performance and infrastructure spending optimism. Financials: Supported by rising yields and better-than-expected bank earnings. On the downside: Healthcare : Dragged by UnitedHealth and pharmaceutical volatility. : Dragged by UnitedHealth and pharmaceutical volatility. Consumer discretionary: Weighed down by Whirlpool and mixed retail trends. As earnings season continues and the Fed concludes its meeting tomorrow, investors should prepare for potential shifts in sentiment. While strong earnings and moderating inflation support the bullish case, risks like trade policy uncertainty and geopolitical tensions remain. Short-term volatility is likely, especially as companies release forward guidance and Wall Street recalibrates expectations for Q3 and Q4. However, many analysts believe the market is well-positioned for continued upside if economic indicators stay resilient and policy decisions remain supportive. The S&P 500 is hovering near its record high, led by tech strength and earnings optimism. is hovering near its record high, led by tech strength and earnings optimism. The Nasdaq continues to outperform, fueled by big tech and AI sector momentum. continues to outperform, fueled by big tech and AI sector momentum. The Dow Jones is relatively flat as industrial and healthcare stocks diverge in performance. is relatively flat as industrial and healthcare stocks diverge in performance. Corporate earnings are generally positive, helping offset macro uncertainty. The Fed's decision and tone tomorrow could influence market direction for the coming weeks. Today's U.S. stock market performance reflects a balanced mix of enthusiasm and caution. Strong earnings, especially in tech, are keeping investor sentiment buoyant, while the start of the Fed's meeting introduces a layer of uncertainty. If the Federal Reserve maintains its current trajectory and companies continue to beat earnings expectations, there's a strong case for continued gains. But with global risks still lurking, staying diversified and tuned into policy developments will be key for navigating the second half of 2025. Q1. What is driving the US stock market today? Strong earnings, tech gains, and the Fed meeting are key factors today. Q2. Why is the Nasdaq rising more than the Dow? Big tech earnings are lifting the Nasdaq while Dow stocks show mixed results. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates. NEXT STORY
News18
an hour ago
- News18
PE/VC investments in India drop 19 pc to USD 26.4 bln in Jan-June
Mumbai, Jul 29 (PTI) Private equity and venture capital funds' bets on India have declined 19 per cent on-year to USD 26.4 billion in January-June 2025 as against USD 32.4 billion recorded in the same period last year, a report said on Tuesday. The investments were higher when compared with the July-December 2024 period's USD 23.8 billion, as per the report by industry lobby grouping IVCA and consultancy firm EY. In terms of number of transactions, 593 deals in January-June 2025 were lower than the 704 in the year-ago period and 649 transactions in the second half of 2024, it said. 'While early signals such as strong GST collections, the recent rate cut by the Reserve Bank of India, and the IPO pipeline are encouraging, the outlook is cautiously optimistic given the concerns on earnings growth and the US-India FTA discussions that are stretching timelines," the consultancy firm's partner Vivek Soni said. He opined that the second half of 2025 could see higher investment activity on better earnings performance by companies and also on culmination of the India-US free trade agreement. Pure-play PE/VC investments excluding the real estate and infrastructure sectors came at USD 18.3 billion, which was 3 per cent lower compared to the USD 18.9 billion in year-ago period, and 13 per cent higher compared to the USD 16.2 billion in July-December 2024. There were 60 large deals of USD 100 million and above during the reporting period, with the USD 1.5 billion buy of New Mountain Capital into Access Healthcare Services being the largest, the report said. The six months saw USD 11.6 billion of exits by such funds, which was almost the same as the year-ago period, but 31 per cent down when compared to the USD 16.8 billion in second half of 2024. PE and VC funds raised USD 8.4 billion across 54 funds during the six months, which was higher both on-year and also from the preceding half of 2024. PTI AA HVA (This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
